Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
04.01. | Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton Sells 25,107 Shares | 11 | MarketBeat | ||
06.12.24 | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 211 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
08.11.24 | Athira exploring strategic alternatives after Alzheimer's failure | 10 | BioPharma Dive | ||
08.11.24 | Athira Pharma GAAP EPS of -$0.75 misses by $0.04 | 2 | Seeking Alpha | ||
07.11.24 | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 186 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
07.11.24 | Athira Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
01.11.24 | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 993 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
18.10.24 | Athira Pharma faces Nasdaq delisting over share price | 12 | Investing.com | ||
18.10.24 | Athira Pharma, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
26.09.24 | Athira Pharma stock plunges to 52-week low of $0.41 | 1 | Investing.com | ||
26.09.24 | Athira Pharma-Aktie stürzt auf 52-Wochen-Tief von 0,41 US-Dollar | 1 | Investing.com Deutsch | ||
20.09.24 | After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule | 3 | FierceBiotech | ||
19.09.24 | Athira Pharma stock faces pivot and workforce cuts amid trial setback - Mizuho | 6 | Investing.com | ||
18.09.24 | Athira Pharma-Aktie erreicht 52-Wochen-Tief bei 0,46 US-Dollar | 7 | Investing.com Deutsch | ||
17.09.24 | Athira Pharma, Inc.: Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
17.09.24 | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
11.09.24 | Athira Pharma stock plunges to 52-week low of $0.46 | 1 | Investing.com | ||
06.09.24 | Athira Pharma general counsel acquires shares, sells for $1.4k | 1 | Investing.com | ||
06.09.24 | Athira Pharma executive sells shares on clinical trial milestone | 2 | Investing.com | ||
06.09.24 | Athira Pharma executive sells shares worth $1,429 | 1 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PALATIN TECHNOLOGIES | 0,947 | +2,27 % | Palatin Technologies Announces $4.7 Mln Direct Offering | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTN) Friday announced that it has entered into agreements with a healthcare-focused institutional investor for the sale of 4.6 million shares... ► Artikel lesen | |
BIOXXMED | 1,020 | 0,00 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Deutsche Wohnen, fox e-mobility, Linus Digital, ThyssenKrupp, Vonovia | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
ORGANOVO | 0,333 | +1,06 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
OCUGEN | 0,691 | +0,51 % | Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa | MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and... ► Artikel lesen | |
INFLARX | 2,508 | -0,95 % | InflaRx: Spannende Phase | Vor wenigen Jahren wäre der Aktienkurs von InflaRx bei so einer Meldung vermutlich durch die Decke gegangen. Immerhin hat das Biotechunternehmen aus Jena mit Listing an der Nasdaq die EU-weite Zulassung... ► Artikel lesen | |
SIRONA BIOCHEM | 0,034 | -12,99 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
BIO-GATE | 0,740 | -7,50 % | Bio-Gate: Prognose reduziert, Potenzial aber weiter hoch | Nach Darstellung von SMC-Research musste Bio-Gate wegen Auftragsverschiebungen die Jahresprognose für 2024 reduzieren. SMC-Analyst Holger Steffen sieht immer noch hohes Potenzial in dem Geschäft, aber... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,746 | +3,32 % | Defence Therapeutics Inc.: Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million | Montreal, Quebec--(Newsfile Corp. - January 31, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing... ► Artikel lesen | |
VAXART | 0,660 | -1,86 % | Vaxart, Inc. - 8-K, Current Report | ||
BURCON NUTRASCIENCE | 0,066 | +0,61 % | Burcon NutraScience Corp: Burcon, ProMan enter manufacturing arrangement | ||
AFFIMED | 1,000 | -0,50 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
IMMUNIC | 0,932 | +0,11 % | EQS-News: Immunic AG: Immunic to Participate in Investor and Scientific Conferences in February | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor and Scientific Conferences in February
04.02.2025 / 12:30 CET/CEST
The issuer is solely... ► Artikel lesen | |
AIM IMMUNOTECH | 0,146 | +5,80 % | AIM ImmunoTech advances Ampligen for avian influenza vaccine | ||
CELLECTAR BIOSCIENCES | 0,300 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,213 | +15,14 % | T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. | LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced... ► Artikel lesen |